ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,851.70
-0.15%
S&P ASX All Technology
3,077.90
0.70%
Brent Oil
82.705
-0.99%
US Dollar vs AUD
1.49993
0.07%
Bitcoin
69,769.73
-2.35%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Rigel Pharmaceuticals Inc (RIGL)

  7. Rigel Pharmaceuticals Inc (RIGL) News

RIGL

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RIGL
DateTimeSourceHeadlineSymbolCompany
08/05/202406:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RIGLRigel Pharmaceuticals Inc
08/05/202406:01PR Newswire (US)Rigel Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
30/04/202422:05PR Newswire (US)Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
11/04/202406:30PR Newswire (US)Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)NASDAQ:RIGLRigel Pharmaceuticals Inc
04/04/202423:05PR Newswire (US)Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & LymphomaNASDAQ:RIGLRigel Pharmaceuticals Inc
12/03/202423:05PR Newswire (US)Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical OfficerNASDAQ:RIGLRigel Pharmaceuticals Inc
06/03/202408:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RIGLRigel Pharmaceuticals Inc
06/03/202408:06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RIGLRigel Pharmaceuticals Inc
06/03/202408:01PR Newswire (US)Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
02/03/202411:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
02/03/202411:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
02/03/202411:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
02/03/202411:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
28/02/202400:05PR Newswire (US)Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
23/02/202400:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RIGLRigel Pharmaceuticals Inc
22/02/202423:50PR Newswire (US)Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®NASDAQ:RIGLRigel Pharmaceuticals Inc
15/02/202406:30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RIGLRigel Pharmaceuticals Inc
07/02/202412:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
07/02/202412:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
07/02/202412:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
03/02/202401:56Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RIGLRigel Pharmaceuticals Inc
26/01/202413:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
26/01/202413:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
26/01/202413:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
26/01/202413:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
26/01/202405:48Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RIGLRigel Pharmaceuticals Inc
09/01/202400:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RIGLRigel Pharmaceuticals Inc
09/01/202400:05PR Newswire (US)Rigel Pharmaceuticals Provides Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
06/01/202408:30PR Newswire (US)Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)NASDAQ:RIGLRigel Pharmaceuticals Inc
05/01/202400:05PR Newswire (US)Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in GliomaNASDAQ:RIGLRigel Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RIGL

Your Recent History

USOTC
VLTLF
Volt Lithium (QB)
LSE
0LW1
Monnari Trade
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved